[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2062570B1 - A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these - Google Patents

A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these Download PDF

Info

Publication number
EP2062570B1
EP2062570B1 EP07747170.4A EP07747170A EP2062570B1 EP 2062570 B1 EP2062570 B1 EP 2062570B1 EP 07747170 A EP07747170 A EP 07747170A EP 2062570 B1 EP2062570 B1 EP 2062570B1
Authority
EP
European Patent Office
Prior art keywords
derivatives
oxycarotenoids
microemulsions
carotenoids
zeaxanthin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07747170.4A
Other languages
German (de)
French (fr)
Other versions
EP2062570A1 (en
EP2062570A4 (en
Inventor
Ricardo Montoya Olvera
José TORRES QUIROGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Organica de C V SA
Original Assignee
Industrial Organica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Organica de C V SA filed Critical Industrial Organica de C V SA
Publication of EP2062570A1 publication Critical patent/EP2062570A1/en
Publication of EP2062570A4 publication Critical patent/EP2062570A4/en
Application granted granted Critical
Publication of EP2062570B1 publication Critical patent/EP2062570B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/179Colouring agents, e.g. pigmenting or dyeing agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/80Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/10Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81Aquaculture, e.g. of fish
    • Y02A40/818Alternative feeds for fish, e.g. in aquacultures

Definitions

  • the present invention is related to a process that noticeably improves the bioavailability of carotenoids by obtaining carotenoids micelles in a lipid matrix in the presence of water.
  • lipid matrix is composed of the free fatty acids, to which the xanthophylls are naturally bound, and the waxes, phospholipids and sterols that naturally occur in the carotenoids extracts, as well as emulsifying agents.
  • lutein, zeaxanthin, and other carotenoids with short chain organic acids like acetic or propionic acids and further processing it occurs the formation of carotenoids micelles in a lipid matrix that have been found to be readily absorbed through the intestine wall.
  • the invention also relates to formulations of carotenoid microemulsions and nanoemulsions that improve the bioavailability in humans, poultry and marine organisms.
  • Carotenoids are terpenoid compounds that besides their typical pigmenting characteristics (yellow, orange or red pigments), function as precursors of molecules with biological activity intervening in different vital biological and physiological processes.
  • Carotenoids are classified in two major groups: carotenes, which are hydrocarbon molecules comprising atoms of carbon and hydrogen only. Representative examples of carotenes include ß-Carotene and Lycopene. And xanthophylls, which are oxygenated derivatives of the carotenes. Examples of xanthophylls include Lutein, Zeaxanthin, Isozeaxanthin, Capsanthin, Capsorubin, Cryptoxanthin, Astaxanthin, 3' Epilutein, and Cantaxanthin.
  • Carotenoids are widely distributed in nature. Total annual production in nature is estimated at over 100 million tons. Carotenoids intervene in the physiology of all living organisms. They are produced in nature by photosynthetic and enzymatic reactions carried by marine microorganisms as microalgae, bacteria, fungii and zooplancton; and in most terrestrial living plants occur in leaves, flowers and fruits.
  • carotenoids are more abundant than in terrestrial organisms and they are responsible for several vital biological, physiological, metabolic and reproductive functions. Carotenoids provide color to marine microalgae and bacteria, krill, salmon, trout, red sea bream, yellow tail tuna, crustaceans etc.
  • Broilers and layers grown in captivity require a given dose of lutein and zeaxanthin in their feed in order to supplement their requirements.
  • Laying hens accumulate lutein, zeaxanthin and cantaxanthin in the yolk, protecting the embryo against the oxidative damage provoked by the free radicals that occur due to the high rate of metabolic reactions in the rapidly developing embryo.
  • Broilers on the other hand, accumulate lutein and zeaxanthin in their adipose tissue as well as in the skin. Such deposits act as reservoirs of carotenoids, and become available when required to perform specific physiological functions.
  • carotenoids are metabolized by terrestrial or marine organism into Vitamin A, and such carotenoids are the only source of Vitamin A for herbivores or omnivores living in their natural environment.
  • Carotenoids act as effective antioxidants in most living organisms. They have the capability to quench free radicals that are produced in metabolic reactions at cellular level, avoiding tissue degradation.
  • Lutein and Zeaxanthin are also present in human breast milk, and in the adipose tissues.
  • Carotenoids occur in a concentrated way in chromoplasts attached to proteins or fibers by non-covalent links. However, chloroplast or chromoplast and other plant structural materials may not be the ideal source of carotenoids for human consumption due to their low bioavailability. Carotenoids occur in food plants as part of the photosynthetic apparatus (green leafy vegetables), dissolved in oil droplets (fruits) or as semi crystalline membrane-bound solids (carrot, tomato).
  • Fatty acid esters of carotenoids such as lutein, zeaxanthin and cryptoxanthin, occur in some fruits (peaches, papaya, peppers), as well as in xanthophyll concentrates obtained from marigold ( Tagetes erecta ) and red peppers ( Capsicum annum ).
  • carotenoids In order that the carotenoids are absorbed by the organism they should previously be freed from their chromoplast matrix. They are thought to be hydrolyzed in the intestinal lumen before mucosal uptake, most likely by the carboxylic ester hydrolase secreted by the pancreas.
  • the carotenoids After the carotenoids are absorbed, they are transported through the enterocytes from the luminal side to the serosal side. They are packaged in chylomicrons and secreted into the thoracic duct, and find their way into the circulating blood via the vena cava inferior.
  • emulsion based food product with quality attributes depends on the selection of the most appropriate raw materials (e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.) and processing conditions(e.g.- mixing, homogenization, pasteurizations, sterilization, etc.).
  • raw materials e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.
  • processing conditions e.g.- mixing, homogenization, pasteurizations, sterilization, etc.
  • An emulsion is a mixture of two immiscible liquids (usually oil and water), with one of them dispersed as small spherical droplets in the other phase. Emulsions can be conveniently classified according to the distribution of the oil and aqueous phases.
  • a system which consist of oil droplets dispersed in an aqueous phase is called an oil-in-water or O/W emulsion (e.g., mayonnaise, milk, cream, soups and sauces).
  • a system which consists of water droplets dispersed in an oil phase is called a water-in oil or W/O (e.g., margarine, butter and spreads).
  • Emulsions are part of a more general class of two-phase systems of matter called colloid.
  • emulsion tends to imply that both the dispersed and the continuous phase are liquid.
  • An emulsifier also known as a surfactant from surface active material or emulgent
  • emulsifier is a substance which stabilizes an emulsion.
  • the main role of the surfactants in food emulsions is to enhance their formation and stability.
  • Surfactants used in the food industry are mainly nonionic (e.g., monoacylglycerols, sucrose esters of fatty acids), anionic (e.g., fatty acids), or zwitterionic (e.g., lecithin).
  • association colloids e.g., micelles, bilayers, vesicles, and reverse micelles.
  • the shape of a micelle is controlled largely by the molecular geometry of its surfactant molecules, but micelle shape also depends on the conditions (such as temperature or pH, and the type and concentration of any added salt).
  • Nonpolar molecules which are normally insoluble or only sparingly soluble in water, can be solubilized in an aqueous surfactant solution by incorporation into micelles or other types of association colloids.
  • Micelles containing solubilizied materials are referred to as microemulsions or swollen micelles whereas the materials solubilizied within the micelle referred to as the solubilizate.
  • US Patent 2,861,891 issued to Bauernfeind and Howard describes a process to obtain a dry powder, obtaining a supersaturated carotene solution by heating in a vegetable oil that afterwards is dispersed in an aqueous gelable colloid solution, and converting the emulsion thus formed into a dry particulate form.
  • Such process involves heating the carotenoids in vegetable oil in order to improve the solubility of the carotenes, lycopene, lutein, zeaxanthin, cryptoxanthin, bixin and methyl bixin, and avoiding the precipitation of carotenoids crystals by incorporating a gelable colloid.
  • a further emulsification step follows in an aqueous colloidal solution that forms a gel capable of producing a dry powder after a spray drying process.
  • the product obtained is a microcrystalline dispersion in edible oil used to impart color to margarine, fruits and vegetables in which the ⁇ carotene occurs in the form of microdispersion in a protective hydrophilic colloid.
  • Cathrein describes in US Patent 5,364,563 a process for producing powdered carotenoid preparations by obtaining a suspension in oil that is brought in contact with superheated steam, producing an emulsion that is spray dried.
  • Eugster et al, in US Patents 5,496,813 and 5,536,504 obtain ultra microemulsions that form spontaneously dispersible concentrates containing xanthophylls esters that have anti tumor activity.
  • Luddecke, et al, in US Patent 5,863,953 describes the obtention of an oil dispersion of carotenoids, which is used to prepare a double dispersion system with particles sizes of 100 microns, stabilized by a protective colloid and emulsifiers.
  • Kolter et al describe in US Patent 5,891,907 stable aqueous solubilizates of carotenoids and vitamins, in which the carotenoids and the water insoluble vitamins with the aid of a nonionic emulsifier, yield a micelle, which particles are smaller than 100 nm.
  • Schweikert et al in US Patent 5,925,684 describe a stable oil in water emulsion consisting of an aqueous phase and an oil phase which is very finely dispersed by means of an emulsifier, and wherein the carotenoid is present in the oil phase in a concentration above the saturation solubility of the carotenoid in the oil at room temperature.
  • Auweter et al describe in US Patent 5,968,251 the preparation of coldwater dispersible powders by preparing a molecular-disperse solution of a carotenoid, with or without an emulsifier and/or edible oil, in a volatile, water-miscible organic solvent at elevated temperature and adding an aqueous solution of a protective colloid; whereupon the hydrophilic solvent is transferred into the aqueous phase, and the hydrophobic phase of the carotenoid results as a nanodisperse phase, removing the solvent by heating the hydrosol and converting it in a water dispersible dry powder.
  • Handelman in US Patent 6,075,058 describes the composition of lutein and zeaxanthin along with cholesterol, olive oil, egg yolk phospholipids, alpha tocopherol and aqueous sodium chloride.
  • the mixture is prepared by mixing the lipid ingredients into ethanol, evaporating the ethanol, and dispersing the lipids as an emulsion in the sodium chloride solution.
  • Bewert et al, in US Patent 6,328,995 describe a procedure to stabilize dry powders which are insoluble in hot water and which contain one or more lipid soluble vitamins or carotenoids, formed in an aqueous dispersion containing a protein, a sugar and potassium and/or sodium phosphates.
  • US-5,959,138 discloses a process to obtain a product having a high content of zeaxanthin, lutein or mixtures thereof, as short chain organic acid diesters of zeaxanthin, lutein or mixtures thereof, that can be used mainly for the pigmentation of broilers and egg yolks, as well as an intermediate in the cantaxanthin ( ⁇ , ⁇ -Carotene-4,4'-dione) and astaxanthin (3,3'-Dihydroxy- ⁇ , ⁇ -carotene,4,4'-dione) synthesis, by reacting extracts obtained from marigold (Tagetes Erecta L.), or plant extracts that contain lutein, zeaxanthin or mixtures thereof in any proportion, with acetic or propionic anhydride under controlled conditions of temperature and pressure.
  • the products obtained in US-5,959,138 may be used in the present process.
  • microemulsions or nanoemulsions of lutein, 3'epilutein, and zeaxanthin diacetates and dipropionates as well as short chain diesters of capsanthin, capsorubin, astaxantin and the acetate and propionate of cryptoxanthin that readily form micelles that are absorbed in the gut and diffuse through the mucous intestine wall.
  • Crystalline solids are composed of atoms, ions, or molecules in a highly ordered geometric pattern (the crystal lattice).
  • the atoms, ions or molecules are held in their positions by electrostatic, dipole and/or London forces.
  • electrostatic, dipole and/or London forces When a pure crystalline solid is heated, the atoms, ions or molecules vibrate more and more rapidly until at a definite temperature the thermal motion of the particles becomes great enough to overcome the forces of attraction. Then the atoms, ions or molecules enter a more random and mobile state, the liquid state.
  • the melting point of a solid is defined as the temperature at which the liquid and solid phases are in equilibrium. A pure solid will generally melt sharply because the forces of attraction between the particles are the same.
  • Such hydrolysis is carried out either in an aqueous media by means of a strong alkali and suitable emulsifiers and temperature, or in a non polar organic media like propylene glycol, also under the action of a strong alkali and temperature. In both cases, as the xanthophylls are free they become insoluble in the reaction media and occur in crystalline form.
  • the reaction mass can be used to prepare pigment premixes or water dispersions, but the physical structure of the carotenoids is always microscopic crystals.
  • the saponified oleoresin mass is subject to several stages of selective organic polar, or non polar solvent extractions, or supercritical CO 2 extractions, and recrystallizations in order to isolate the carotenoids from the other components of the mass.
  • the carotenoids as expected, occur in crystalline form.
  • the micelles, microemulsions and nanoemulsions of oxycarotenoids derivatives are obtained during the reaction of such oxycarotenoids with short chain organic acids like acetic or propionic acid.
  • Such microscopic emulsions occur during the course of such reaction under controlled conditions and further processing.
  • the carotenoids derivatives obtained by this process do have melting points that are lower as compared to the melting points of the free carotenoids.
  • the carotenoid derivatives crystals under certain conditions of temperature, time, and in the presence of lipids, emulsifiers, and moisture, form stable micelles occluded in the lipid matrix and remain as such at normal conditions of temperature and pressure.
  • Such lipid carotenoid micelles contain melt down oxycarotenoids derivatives, and are non-crystalline.
  • the patent also discloses a process for the preparation of microemulsions and micelles and its uses in administering lutein and zeaxanthin diacetates or dipropionates, and those of other oxycarotenoids derivatives to humans, as well as for the pigmentation of broilers, egg yolks, and marine species as salmonids, crustaceans and fish.
  • microemulsions obtained can be reduced in size to obtain nanoemulsions by intense high speed and high shear mechanical agitators for a period of 3 to 4 hours, or by emulsifying machines operating at pressures of the order of 3,000 to 4,000 psi.
  • microemulsions obtained in step h) may be dispersed in an aqueous or lipid media, suitable to be incorporated in human supplements or foods, or feeds for pets, poultry or aquatic animals at a temperature of between about 40 to 70o C in order to, among other applications: noticeably improving the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin, for the purpose of pigmentation of broilers skin and egg yolks or improving the bioavailability of the carotenoids derivatives obtained from: lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms such as shrimp and crustaceans, salmon, trout, red sea bream, yellow tail tuna.
  • the aqueous or lipid media microemulsions dispersion may comprise: water containing carotenoids derivatives obtained from the following carotenoids: lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent the degeneration of human tissues due to the presence of free radicals; or oil, preferebly fish oil with a high content of omega 3 fatty acids, containing carotenoids derivatives which noticeably improves the bioavailability of oxycarotenoid derivatives like lutein, 3'epilutein, zeaxanthin, meso zeaxanthin, iso zeaxanthin, capsanthin, capsorubin and astaxanthin diacetates or dipropionates in humans which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effects of
  • microemulsion of carotenoids derivatives obtained from: lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, and astaxanthin obtained in step h) may also be encapsulated by suitable maltodextrins; sugars; animal, vegetable or fish gelatins in order to prepare beadlets for supplementing the nutrition of humans.
  • the above described process helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
  • carotenoids are unstable and tend to degrade when exposed to light, oxygen and organic or inorganic acids at elevated temperatures. While processing carotenoids under such conditions all operations should be performed either under vacuum or under an inert atmosphere such as a nitrogen atmosphere. It was observed a remarkable stability of the short chain diester oxycarotenoids, namely diacetates or dipropionates, after being subject to such conditions.
  • the diacetate and the dipropionates are derivatives of carotenoids of non polar nature, they tend to melt down and remain as micro or nanospheres dispersed in the lipid matrix at a lower temperature than the melting point of the pure carotenoids.
  • the carotenoids derivatives crystals By increasing the temperature to 90-110 °C under agitation and under an inert atmosphere, the carotenoids derivatives crystals are melted down in the lipid non polar matrix producing a homogeneous phase. Although the melting points of pure carotenoids crystals are high; we observed that the original composition of the matrix and the incorporation of moisture, vegetable oil, additional fatty acids and emulsifiers, as well as a suitable control of the pH media during the melting process, they interact with the carotenoids crystals provoking in situ a sensible decrease of the melting point of the oxycarotenoids derivatives, producing a dispersion of non-crystalline nanoparticles of carotenoids in micellar form with average particle sizes of 2-5 nanometers.
  • the present process generates oxycarotenoid derivatives that interact with the components of the matrix and at the given conditions of temperature, time and agitation, produce carotenoids compounds in a non-crystalline state that upon their incorporation in micelles notably improve their absorption and bioavailability.
  • the micelles obtained can be diluted with more lipid material.
  • lipid material may comprise one or more members selected from the group consisting of vegetable oil, mineral oil, medium chain tryglicerides (MCT) oil (i.e. a triglyceride oil in which the carbohydrate chain has about 8-12 carbon atoms), oily fatty acids, isopropyl myristate, oily fatty alcohols, esters of sorbitol and fatty acids, oily sucrose esters or mixtures thereof.
  • MCT medium chain tryglicerides
  • Examples of phospholipids which may be used in the emulsions of the invention are soy lecithins, lecithins; Epikuron 120 TM which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; Ovothin 160 TM or Ovothin 200 TM . Phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; a purified phospholipid mixture, e.g.
  • An impure solid compound melts at a lower temperature and over a wider range.
  • a solid's compound's melting point may be lowered (depressed) by the addition of a soluble material to the solution.
  • the melting points of the pure carotenoids are higher in regard to the melting points of their corresponding derivatives. Therefore in the process to obtain carotenoids derivatives from pure carotenoids, the melting point of oxycarotenoids is reduced from 50 to 116° C with respect to the melting point of the pure carotenoid, when the diacetate derivatives are incorporated in the process; and the melting point of oxycarotenoids is reduced from 30 to 50° C with respect to the melting point of the pure carotenoid, when propionate derivatives are incorporated in the process. As the molecular weight of the carotenoid derivative is larger, then the melting point of such derivative is further reduced, as compared to the melting point of the pure carotenoid.
  • the obtained micelles can be easily dispersed in water, forming stable microemulsions or nanoemulsions, composed of an internal homogeneous lipophilic phase of carotenoids derivatives that do not contain any crystals, and an external hydrophylic phase formed by lipids and emulsifiers. It is a true oxycarotenoid derivatives solute contained in the micelles. Due to its soft nature such lipid carotenoid derivatives can be easily micronized by means of a homogenizing machine into a microemulsion or a nanoemulsion. Crystalline structures per se are hard to break by mechanical means and therefore are very difficult to be worked into microemulsions and almost impossible to produce nanoemulsions in a non polar media.
  • the pigmentation efficiency is noticeably improved as compared to the pigmentation obtained by premixes or water dispersions that contain the oxycarotenoids in crystalline form.
  • the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 1 kg of a vegetable oil or fish oil, fatty acid and an emulsifier mixture is added.
  • the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C
  • the temperature of the reactor is increased to 100° C until all of the lutein diacetate crystals disappear, as can be observed under a 100X microscope objective.
  • the mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension.
  • the above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
  • the colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
  • the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 500 gr of oleic acid.
  • the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
  • the temperature of the reactor is increased to 95° C until all of the carotenoids diacetate crystals disappear, as can be observed under a 100X microscope objective.
  • the mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension.
  • the above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
  • the colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
  • the oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • the mass is rinsed several times with lukewarm water several times to remove any acid traces and salts.
  • the vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
  • the temperature is raised to 100°C under an atmosphere of nitrogen for a period of 180 minutes until no carotenoids crystals are observed under a 100X microscope objective.
  • the colloidal suspension can be dispersed in solid carriers, vegetable oils or diluted in water.
  • Group A and Group B Two identical groups (Group A and Group B) of three weeks old broilers were placed in suitable pens, containing 50 chicken each. They were fed identical feeds (ad-libitum) containing different pigmenting concentrates.
  • Group A broilers feed contained 80 ppm of a blend of micellar lutein diacetate and micellar zeaxanthin diacetate prepared according to example 1.
  • Group B broilers feed contained 90 ppm of a standard lutein pigment (saponified and dispersed in water) plus 3 grams of cantaxanthin.
  • a Minolta Chromameter was used to determine the pigment reading in the breast skin of each refrigerated broiler.
  • the average readings obtained for each group are as follows: Group Yellowness (b*) Redness (a*) Luminosity A 27.12 -1.19 76.12 B 26.21 0.90 74.09

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Insects & Arthropods (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)

Description

    BACKGROUND OF THE INVENTION A. FIELD OF THE INVENTION
  • The present invention is related to a process that noticeably improves the bioavailability of carotenoids by obtaining carotenoids micelles in a lipid matrix in the presence of water. Such lipid matrix is composed of the free fatty acids, to which the xanthophylls are naturally bound, and the waxes, phospholipids and sterols that naturally occur in the carotenoids extracts, as well as emulsifying agents. During the esterification reaction of lutein, zeaxanthin, and other carotenoids with short chain organic acids like acetic or propionic acids and further processing, it occurs the formation of carotenoids micelles in a lipid matrix that have been found to be readily absorbed through the intestine wall. Such absorption is a noticeable improvement as compared to the lower bioavailability of carotenoid crystals. The invention also relates to formulations of carotenoid microemulsions and nanoemulsions that improve the bioavailability in humans, poultry and marine organisms.
  • B. DESCRIPTION OF THE RELATED ART
  • Carotenoids are terpenoid compounds that besides their typical pigmenting characteristics (yellow, orange or red pigments), function as precursors of molecules with biological activity intervening in different vital biological and physiological processes.
  • Over 600 different carotenoids have been recognized in nature. Carotenoids are classified in two major groups: carotenes, which are hydrocarbon molecules comprising atoms of carbon and hydrogen only. Representative examples of carotenes include ß-Carotene and Lycopene. And xanthophylls, which are oxygenated derivatives of the carotenes. Examples of xanthophylls include Lutein, Zeaxanthin, Isozeaxanthin, Capsanthin, Capsorubin, Cryptoxanthin, Astaxanthin, 3' Epilutein, and Cantaxanthin.
  • Carotenoids are widely distributed in nature. Total annual production in nature is estimated at over 100 million tons. Carotenoids intervene in the physiology of all living organisms. They are produced in nature by photosynthetic and enzymatic reactions carried by marine microorganisms as microalgae, bacteria, fungii and zooplancton; and in most terrestrial living plants occur in leaves, flowers and fruits.
  • In flowers and fruits carotenoids impart vivid yellow, orange and red colors.
  • In birds carotenoids play the role of vital functions as well as cosmetic purposes, they differentiate genders, and are indicative of sexual maturity and attraction.
  • In marine organism carotenoids are more abundant than in terrestrial organisms and they are responsible for several vital biological, physiological, metabolic and reproductive functions. Carotenoids provide color to marine microalgae and bacteria, krill, salmon, trout, red sea bream, yellow tail tuna, crustaceans etc.
  • No animal species are capable of synthesizing carotenoids. Therefore, they should obtain their requirements through the diet. Broilers and layers grown in captivity require a given dose of lutein and zeaxanthin in their feed in order to supplement their requirements. Laying hens accumulate lutein, zeaxanthin and cantaxanthin in the yolk, protecting the embryo against the oxidative damage provoked by the free radicals that occur due to the high rate of metabolic reactions in the rapidly developing embryo. Broilers, on the other hand, accumulate lutein and zeaxanthin in their adipose tissue as well as in the skin. Such deposits act as reservoirs of carotenoids, and become available when required to perform specific physiological functions.
  • Some carotenoids are metabolized by terrestrial or marine organism into Vitamin A, and such carotenoids are the only source of Vitamin A for herbivores or omnivores living in their natural environment.
  • Carotenoids act as effective antioxidants in most living organisms. They have the capability to quench free radicals that are produced in metabolic reactions at cellular level, avoiding tissue degradation.
  • Extensive research in the past years indicate that the presence of Lutein and Zeaxanthin in the macula helps the prevention of age related macular degeneration in humans, as well as avoids the development of cataracts. Lutein and Zeaxanthin are also present in human breast milk, and in the adipose tissues.
  • Dark green leafy vegetables, tomatoes, as well as yellow corn, and many fruits like oranges, mangoes, grapefruit, etc. are the natural source of dietary carotenoids. Carotenoids occur in a concentrated way in chromoplasts attached to proteins or fibers by non-covalent links. However, chloroplast or chromoplast and other plant structural materials may not be the ideal source of carotenoids for human consumption due to their low bioavailability. Carotenoids occur in food plants as part of the photosynthetic apparatus (green leafy vegetables), dissolved in oil droplets (fruits) or as semi crystalline membrane-bound solids (carrot, tomato). Fatty acid esters of carotenoids, such as lutein, zeaxanthin and cryptoxanthin, occur in some fruits (peaches, papaya, peppers), as well as in xanthophyll concentrates obtained from marigold (Tagetes erecta) and red peppers (Capsicum annum).
  • In order that the carotenoids are absorbed by the organism they should previously be freed from their chromoplast matrix. They are thought to be hydrolyzed in the intestinal lumen before mucosal uptake, most likely by the carboxylic ester hydrolase secreted by the pancreas.
  • In animals, the absorption of carotenoids is generally accepted to follow that of lipids- i.e. emulsification and incorporation into mixed micelles, which are then absorbed by the mucosa of the small intestine, mainly in the duodenum, in parallel with fat digestion and absorption. They are transported through the unstirred water layer and taken up by the enterocytes by passive diffusion.
  • It is in the intestine mucous wall that such passive diffusion is improved if the carotenoids are dissolved in a lipid forming a micelle in an aqueous media, rather than if they are in crystalline form. Crystals are not the ideal physical form for this diffusion to occur, nor are carotenoids crystals readily incorporated into micelles. If the carotenoids enter the gut already as microemulsions, or as nanoemulsions, the formation of micelles is facilitated.
  • After the carotenoids are absorbed, they are transported through the enterocytes from the luminal side to the serosal side. They are packaged in chylomicrons and secreted into the thoracic duct, and find their way into the circulating blood via the vena cava inferior.
  • Among the main factors that affect the bioavailability of xanthophylls by organisms are: physical form in the source (food matrix), the structure of the xanthophylls molecules, and the interaction of the xanthophylls with other nutrients, mainly lipids. Therefore, it would be highly desirable to develop carotenoids compounds, derivatives or formulations with improved stability, absorption and bioavailability.
  • Many natural and processed foods consist either partly or wholly as emulsions or have been in an emulsified state at some time during their production. The manufacture of an emulsion based food product with quality attributes depends on the selection of the most appropriate raw materials (e.g., water, oil, emulsifier, thickening agents, minerals, acids, colorants, flavours, vitamins, etc.) and processing conditions(e.g.- mixing, homogenization, pasteurizations, sterilization, etc.).
  • An emulsion is a mixture of two immiscible liquids (usually oil and water), with one of them dispersed as small spherical droplets in the other phase. Emulsions can be conveniently classified according to the distribution of the oil and aqueous phases. A system which consist of oil droplets dispersed in an aqueous phase is called an oil-in-water or O/W emulsion (e.g., mayonnaise, milk, cream, soups and sauces). A system which consists of water droplets dispersed in an oil phase is called a water-in oil or W/O (e.g., margarine, butter and spreads). Emulsions are part of a more general class of two-phase systems of matter called colloid. Although the terms colloid and emulsion are sometimes used interchangeably, emulsion tends to imply that both the dispersed and the continuous phase are liquid. An emulsifier (also known as a surfactant from surface active material or emulgent) is a substance which stabilizes an emulsion. The main role of the surfactants in food emulsions is to enhance their formation and stability. Surfactants used in the food industry are mainly nonionic (e.g., monoacylglycerols, sucrose esters of fatty acids), anionic (e.g., fatty acids), or zwitterionic (e.g., lecithin). Surfactants aggregate spontaneously in solution to form a variety of thermodynamically stable structures know as association colloids (e.g., micelles, bilayers, vesicles, and reverse micelles). The shape of a micelle is controlled largely by the molecular geometry of its surfactant molecules, but micelle shape also depends on the conditions (such as temperature or pH, and the type and concentration of any added salt).
  • Nonpolar molecules, which are normally insoluble or only sparingly soluble in water, can be solubilized in an aqueous surfactant solution by incorporation into micelles or other types of association colloids. Micelles containing solubilizied materials are referred to as microemulsions or swollen micelles whereas the materials solubilizied within the micelle referred to as the solubilizate.
  • In view of the above referred needs, applicants developed a process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates and dipropionates derivatives that are readily incorporated in the digestive system as micelles providing an improved bioavailabilty, as compared to the bioavailability of carotenoids that are ingested in crystalline form.
  • US Patent 2,861,891 issued to Bauernfeind and Howard describes a process to obtain a dry powder, obtaining a supersaturated carotene solution by heating in a vegetable oil that afterwards is dispersed in an aqueous gelable colloid solution, and converting the emulsion thus formed into a dry particulate form. Such process involves heating the carotenoids in vegetable oil in order to improve the solubility of the carotenes, lycopene, lutein, zeaxanthin, cryptoxanthin, bixin and methyl bixin, and avoiding the precipitation of carotenoids crystals by incorporating a gelable colloid. A further emulsification step follows in an aqueous colloidal solution that forms a gel capable of producing a dry powder after a spray drying process. The product obtained is a microcrystalline dispersion in edible oil used to impart color to margarine, fruits and vegetables in which the βcarotene occurs in the form of microdispersion in a protective hydrophilic colloid.
  • US Patent 3,523,138 issued to Grant describes the improved bioavailability of carotenoids in poultry, after a saponification reaction has taken place in order to free the xanthophylls from the long chain fatty acid esters.
  • US Patent 3,535,426 issued to Hawks discloses that a saponified mixture of xanthophylls become more stable, and consequently more bioavailable, when admixed with a fat and ethoxyquinolein.
  • Cathrein describes in US Patent 5,364,563 a process for producing powdered carotenoid preparations by obtaining a suspension in oil that is brought in contact with superheated steam, producing an emulsion that is spray dried.
  • Eugster et al, in US Patents 5,496,813 and 5,536,504 obtain ultra microemulsions that form spontaneously dispersible concentrates containing xanthophylls esters that have anti tumor activity.
  • Gellenbeck in US Patent 5,827,539 obtains a finely ground mixture of carotenoids with an oil and a spray dried encapsulated form that is water dispersible.
  • Luddecke, et al, in US Patent 5,863,953 describes the obtention of an oil dispersion of carotenoids, which is used to prepare a double dispersion system with particles sizes of 100 microns, stabilized by a protective colloid and emulsifiers.
  • Sanders and Herink published in WO9947001 the increased bioavailability of lutein and zeaxanthin in humans and poultry using isolecithin and lecithin.
  • Kolter et al, describe in US Patent 5,891,907 stable aqueous solubilizates of carotenoids and vitamins, in which the carotenoids and the water insoluble vitamins with the aid of a nonionic emulsifier, yield a micelle, which particles are smaller than 100 nm.
  • Luddecke et al, describe in US Patent 5,895,659 the preparation of finely dispersed carotenoids or retinoid suspensions by dissolving the carotenoid or retinoid in a volatile, water-miscible organic solvent, under elevated pressures, and immediately after 10 seconds, mix the solution with an aqueous medium containing an emulsifier.
  • Schweikert et al in US Patent 5,925,684 describe a stable oil in water emulsion consisting of an aqueous phase and an oil phase which is very finely dispersed by means of an emulsifier, and wherein the carotenoid is present in the oil phase in a concentration above the saturation solubility of the carotenoid in the oil at room temperature.
  • Auweter et al, describe in US Patent 5,968,251 the preparation of coldwater dispersible powders by preparing a molecular-disperse solution of a carotenoid, with or without an emulsifier and/or edible oil, in a volatile, water-miscible organic solvent at elevated temperature and adding an aqueous solution of a protective colloid; whereupon the hydrophilic solvent is transferred into the aqueous phase, and the hydrophobic phase of the carotenoid results as a nanodisperse phase, removing the solvent by heating the hydrosol and converting it in a water dispersible dry powder.
  • Gellenbeck in US Patent 5,976,575 describes the grinding of a mixture of carotenoids and oil to reduce the carotenoids particle size, emulsifying the mixture with an encapsulating mixture and drying the emulsion.
  • Handelman in US Patent 6,075,058 describes the composition of lutein and zeaxanthin along with cholesterol, olive oil, egg yolk phospholipids, alpha tocopherol and aqueous sodium chloride. The mixture is prepared by mixing the lipid ingredients into ethanol, evaporating the ethanol, and dispersing the lipids as an emulsion in the sodium chloride solution.
  • Kowalski et al, describe in US Patent 6,093,348 a method for the manufacture of carotenoid powders, weherein an aqueous suspension of the carotenoid is heated to melt the carotenoid in the presence of a surfactant and a protective colloid under high temperatures and high pressures (HTHP process). The suspension is then homogenized under high pressure to form an emulsion. And the resulting emulsion is dried to obtain the carotenoid powder.
  • Schliapalius in US Patent 6,132,790 describes a composition of a carotenoid in oil, a dispersion of a water dispersible matrix and a stabilizer, and a non-oil solvent and an emulsifier, all of natural sources.
  • Koguchi, et al describe in US Patent 6,261,622 a method to provide a water-dispersible carotenoid preparation which can be added to various aqueous compositions with retaining dispersion stability even at low temperature, by dispersing pulverized carotenoids crystals with soybean extract fibers as emulsion stabilizer.
  • Bewert et al, in US Patent 6,328,995 describe a procedure to stabilize dry powders which are insoluble in hot water and which contain one or more lipid soluble vitamins or carotenoids, formed in an aqueous dispersion containing a protein, a sugar and potassium and/or sodium phosphates.
  • Stein et al, describe in US Patent 6,406,735 a process for the preparation of a pulverous composition of a finely divided carotenoid or retinoid comprising; forming a suspension of the active ingredient in a water-immiscible organic solvent containing an antioxidant and/or an oil, feeding the suspension through a heat exchanger and heating the suspension to a high temperature for a 5 seconds residence time, rapidly mixing the solution with an aqueous swellable colloid and further removing the organic solvent to obtain the pulverous preparation, all steps processed in a continuous sequence.
  • Guerra-Santos, et al describe in US Patent 6,936,279 the obtention of microcrystalline form of carotenoids, particularly zeaxanthin, in an oily carrier. The "coarse-grained" carotenoids is dissolved in a suitable solvent as tetrahydrofuran, and mixed with a vegetable oil and an emulsifier. The mixture is injected along with an inert gas into a vacuum chamber in order to remove the solvent in a flash manner, not allowing the carotenoids crystals to grow. They obtain a microcrystalline suspension in the oil carrier.
  • US-5,959,138 discloses a process to obtain a product having a high content of zeaxanthin, lutein or mixtures thereof, as short chain organic acid diesters of zeaxanthin, lutein or mixtures thereof, that can be used mainly for the pigmentation of broilers and egg yolks, as well as an intermediate in the cantaxanthin (β,β-Carotene-4,4'-dione) and astaxanthin (3,3'-Dihydroxy-β,β-carotene,4,4'-dione) synthesis, by reacting extracts obtained from marigold (Tagetes Erecta L.), or plant extracts that contain lutein, zeaxanthin or mixtures thereof in any proportion, with acetic or propionic anhydride under controlled conditions of temperature and pressure. The products obtained in US-5,959,138 may be used in the present process.
  • Therefore to our knowledge, the novelty that is being disclosed in this patent has no previous precedings. Furthermore, none of the above described patents completely avoids the formation of carotenoids crystals, which as previously described, affect the absorption and bioavailability of carotenoids.
  • By the process of the present invention, it is possible to obtain microemulsions or nanoemulsions of lutein, 3'epilutein, and zeaxanthin diacetates and dipropionates, as well as short chain diesters of capsanthin, capsorubin, astaxantin and the acetate and propionate of cryptoxanthin that readily form micelles that are absorbed in the gut and diffuse through the mucous intestine wall.
  • Crystalline solids are composed of atoms, ions, or molecules in a highly ordered geometric pattern (the crystal lattice). The atoms, ions or molecules are held in their positions by electrostatic, dipole and/or London forces. When a pure crystalline solid is heated, the atoms, ions or molecules vibrate more and more rapidly until at a definite temperature the thermal motion of the particles becomes great enough to overcome the forces of attraction. Then the atoms, ions or molecules enter a more random and mobile state, the liquid state. The melting point of a solid is defined as the temperature at which the liquid and solid phases are in equilibrium. A pure solid will generally melt sharply because the forces of attraction between the particles are the same. However, the presence of a foreign particle in a crystal lattice interrupts its uniform structure and the forces of attraction are weakened. An "impure" compound melts at a lower temperature and over a wider range. Thus, in the process of the present invention, the melting point of carotenoid derivatives is lowered (depressed) by the addition of a soluble material to the solution.
  • It is a common practice in the pigment industry to carry on a saponification reaction, or hydrolysis, of the fatty acids diesters of lutein and zeaxanthin as they naturally occur in the oleoresin of Tagetes erecta, in order to free the above mentioned carotenoids. It is also a common practice to hydrolyze the oleoresin of Capsicum annum to free the capsanthin and capsorubin from the fatty acids, as they occur in the natural form.
  • Such hydrolysis is carried out either in an aqueous media by means of a strong alkali and suitable emulsifiers and temperature, or in a non polar organic media like propylene glycol, also under the action of a strong alkali and temperature. In both cases, as the xanthophylls are free they become insoluble in the reaction media and occur in crystalline form.
  • The reaction mass can be used to prepare pigment premixes or water dispersions, but the physical structure of the carotenoids is always microscopic crystals.
  • In the different purification and refinement processes aimed to obtain carotenoids of high purity, the saponified oleoresin mass is subject to several stages of selective organic polar, or non polar solvent extractions, or supercritical CO2 extractions, and recrystallizations in order to isolate the carotenoids from the other components of the mass. At the end of such purification processes, the carotenoids, as expected, occur in crystalline form.
  • In the process of the present invention the micelles, microemulsions and nanoemulsions of oxycarotenoids derivatives, are obtained during the reaction of such oxycarotenoids with short chain organic acids like acetic or propionic acid. Such microscopic emulsions occur during the course of such reaction under controlled conditions and further processing. The carotenoids derivatives obtained by this process do have melting points that are lower as compared to the melting points of the free carotenoids. Surprisingly the carotenoid derivatives crystals under certain conditions of temperature, time, and in the presence of lipids, emulsifiers, and moisture, form stable micelles occluded in the lipid matrix and remain as such at normal conditions of temperature and pressure. Such lipid carotenoid micelles contain melt down oxycarotenoids derivatives, and are non-crystalline.
  • SUMMARY OF THE INVENTION
  • It is therefore a main object of the present invention, to provide a process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates or dipropionates derivatives, which are readily incorporated in the digestive system as micelles providing an improved bioavailability, as compared to the bioavailability of carotenoids that are ingested in diverse preparations that contain microscopic carotenoids crystals.
  • The patent also discloses a process for the preparation of microemulsions and micelles and its uses in administering lutein and zeaxanthin diacetates or dipropionates, and those of other oxycarotenoids derivatives to humans, as well as for the pigmentation of broilers, egg yolks, and marine species as salmonids, crustaceans and fish.
  • These and other objects and advantages of the present invention will become apparent to those persons having an ordinary skill in the art, from the following detailed description of the embodiments of the invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The process of the present invention will now be described making reference to a preferred embodiment thereof and to specific examples of use and application of the product, wherein the process of the present invention comprising:
    1. a) Incorporating the oxycarotenoids derivatives comprising diacetates and dipropionates, obtained from: lutein, 3'epilutein, zeaxanthin, mesozeaxanthin, capsanthin, astaxanthin, and cryptoxanthin monoacetate and cryptoxanthin monopropionate, or their mixtures with the components of a vegetable matrix or components of similar nature, comprising fatty acids, phospholipids, emulsifiers and/or sterols inside a reactor;
    2. b) Raising the temperature of the reactor to a temperature of between about 60 to 70o C under a nitrogen atmosphere;
    3. c) Adding a surfactant, or mix of surfactants, in an amount of 5 to 50% by weight to the reactor mix, such as Tween 80, comprising polyoxyethylene sorbitan, particularly polysorbate 20-85 such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 70, polysorbate 80(Tween 80), polysorbate 81, polysorbate 85; polyoxyethylene stearates (polyoxyethylene(40) stearate), polyoxyethylene(8) stearate and polyoxyethylene (40) stearate; polyoxyethylene oleates; polyoxyethylene laurates;. polyoxyethylene castor oil derivatives; sorbitan esters; polyoxyethylene sorbitan fatty acid esters; poloxamers such as Pluronic F-65LF; Pluronic L-62LF and Pluronic L62D (BASF Wyandotte Corp.) or tyloxapol, polyoxyethylene fatty acid esters such as EMULPHOR (GAF Corp).
    4. d) Stirrring the mix obtained in step c) during a period of two hours;
    5. e) Adding to the mix obtained in step d) a phospholipid in an amount of 5 to 50% by weight, said phospholipids selected from the group comprising: lecithins; Epikuron 120 (Lucas Meyer, which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids); Ovothin 160 or Ovothin 200 (Lucas Meyer, phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids); or a purified phospholipid mixture, such as that obtained from egg yolk, or Lipoid E-80 (Lipoid AG, which is a phospholipid mixture comprising about 50% phosphatidylcholine, 5% phosphatidylethanolamine, 3.6% non-polar lipids and about 2% sphingomyeline);
    6. f) Stirring the mix obtained in step e) during a period of time of one hour in order to homogenize the mix,
    7. g) Adding to the mixture obtained in step f) water in an amount of 1 to 40 % by weight;
    8. h) Raising the temperature of the mix obtained in step g) at a temperature of between about 90 to 110o C while maintaining the pH of the lipid matrix at from 5.5 to 8.5, preferably at a pH of from 6.5 to 7.0 and submit the mix to a refluxing cycle during a time period of between about 2 to 10 hours until it is observed under a 100X microscope that the carotenoids derivatives crystals melt down in the lipid non polar matrix, thus producing oxycarotenoids derivatives microemulsions in a ratio of 0.001% to 40% by weight wherein the microemulsions comprises an internal homogeneous dispersed lipophilic phase of melted oxycarotenoids derivatives, and an external hydrophilic phase mainly formed by vegetable lipids and emulsifiers. The order of steps g) and h) may be inverted.
  • The microemulsions obtained can be reduced in size to obtain nanoemulsions by intense high speed and high shear mechanical agitators for a period of 3 to 4 hours, or by emulsifying machines operating at pressures of the order of 3,000 to 4,000 psi.
  • The microemulsions obtained in step h) may be dispersed in an aqueous or lipid media, suitable to be incorporated in human supplements or foods, or feeds for pets, poultry or aquatic animals at a temperature of between about 40 to 70o C in order to, among other applications: noticeably improving the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin, for the purpose of pigmentation of broilers skin and egg yolks or improving the bioavailability of the carotenoids derivatives obtained from: lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms such as shrimp and crustaceans, salmon, trout, red sea bream, yellow tail tuna.
  • The aqueous or lipid media microemulsions dispersion may comprise: water containing carotenoids derivatives obtained from the following carotenoids: lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent the degeneration of human tissues due to the presence of free radicals; or oil, preferebly fish oil with a high content of omega 3 fatty acids, containing carotenoids derivatives which noticeably improves the bioavailability of oxycarotenoid derivatives like lutein, 3'epilutein, zeaxanthin, meso zeaxanthin, iso zeaxanthin, capsanthin, capsorubin and astaxanthin diacetates or dipropionates in humans which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effects of free radicals and singlet oxygen, to improve the hearth and cardiovascular conditions, and at the same time to help reduce the risk of macular degeneration and the formation of cataracts.
  • The microemulsion of carotenoids derivatives obtained from: lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, and astaxanthin obtained in step h) may also be encapsulated by suitable maltodextrins; sugars; animal, vegetable or fish gelatins in order to prepare beadlets for supplementing the nutrition of humans.
  • The above described process helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature.
  • Most of the carotenoids are unstable and tend to degrade when exposed to light, oxygen and organic or inorganic acids at elevated temperatures. While processing carotenoids under such conditions all operations should be performed either under vacuum or under an inert atmosphere such as a nitrogen atmosphere. It was observed a remarkable stability of the short chain diester oxycarotenoids, namely diacetates or dipropionates, after being subject to such conditions.
  • Since the diacetate and the dipropionates are derivatives of carotenoids of non polar nature, they tend to melt down and remain as micro or nanospheres dispersed in the lipid matrix at a lower temperature than the melting point of the pure carotenoids. The presence of lipids, free fatty acids, waxes and sterols, as occur in the natural oleoresin, called lipid matrix, also help to reduce the melting point of the oxycarotenoids derivatives.
  • It was found that after the hydrolysis of xanthophylls fatty acid esters is completed, and the excess alkali has been neutralized by means of a diluted acid like phosphoric acid, acetic acid, hydrochloric acid, perchloric acid, or mixtures thereof, and brought about to a pH from 5-9, preferably a pH of 5.5-6.5, a two phase system is formed. The organic phase that contains the carotenoids crystals is rinsed several times with warm water to remove any acid and salts traces. The supernatant or lipid mass mainly consists of free fatty acids, and minor compounds like waxes, phospholipids and sterols, that occur naturally with the carotenoids esters. When this lipid mass is dried under vacuum and the carotenoids are esterified according to US Patent No. 5,959,138 with acetic anhydride or propionic anhydride, a supernatant organic phase is obtained where the carotenoids short chain diesters crystals are embedded. The compounds present in the organic matrix "impurities" interact by remarkably decreasing the carotenoids short chain diesters' melting point, and help to improve the stability of the oxycarotenoids derivatives during the heating process. The main fatty acids are myristic, palmitic and stearic as naturally occur in the Tagetes erecta extract; and oleic, linoleic and linolenic acids are found in the Capsicum annum extracts.
  • By increasing the temperature to 90-110 °C under agitation and under an inert atmosphere, the carotenoids derivatives crystals are melted down in the lipid non polar matrix producing a homogeneous phase. Although the melting points of pure carotenoids crystals are high; we observed that the original composition of the matrix and the incorporation of moisture, vegetable oil, additional fatty acids and emulsifiers, as well as a suitable control of the pH media during the melting process, they interact with the carotenoids crystals provoking in situ a sensible decrease of the melting point of the oxycarotenoids derivatives, producing a dispersion of non-crystalline nanoparticles of carotenoids in micellar form with average particle sizes of 2-5 nanometers. The present process generates oxycarotenoid derivatives that interact with the components of the matrix and at the given conditions of temperature, time and agitation, produce carotenoids compounds in a non-crystalline state that upon their incorporation in micelles notably improve their absorption and bioavailability.
  • The micelles obtained can be diluted with more lipid material. Such lipid material may comprise one or more members selected from the group consisting of vegetable oil, mineral oil, medium chain tryglicerides (MCT) oil (i.e. a triglyceride oil in which the carbohydrate chain has about 8-12 carbon atoms), oily fatty acids, isopropyl myristate, oily fatty alcohols, esters of sorbitol and fatty acids, oily sucrose esters or mixtures thereof. Examples of phospholipids which may be used in the emulsions of the invention are soy lecithins, lecithins; Epikuron 120 which is a mixture of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; Ovothin 160 or Ovothin 200. Phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; a purified phospholipid mixture, e.g. such which is obtained from egg yolk; Lipoid E-80 (Lipoid AG, Ludwigshafen); fatty acids as myristic, palmitic, stearic as naturally occur in the Tagetes erecta extract; and oleic, linoleic and linolenic acids emulsifiers like Polyoxyethylene sorbitan particularly polysorbate 20-85 such as polysorbate 20, polysorbate 40 polysorbate 60, polysorbate 65, polysorbate 70, polysorbate 80 (Tween 80), polysorbate 81, polysorbate 85, polyoxyethylene (8) stearate and polyoxyethylene (40), etc. in order to elaborate different preparations or formulations.
  • An impure solid compound melts at a lower temperature and over a wider range. Thus a solid's compound's melting point may be lowered (depressed) by the addition of a soluble material to the solution.
  • The melting points (mp) of pure carotenoids, as well as the melting points of some of their derivatives are as follows (The Merck Index, Twelfth Edition, 1996):
    Lutein mp 190o C
    Lutein Diacetate mp 170o C
    Lutein Dipropionate mp 138o C
    Lutein Dipalmitate mp 92o C
    Zeaxanthin mp 215o C
    Zeaxanthin Diacetate mp 155o C
    Zeaxanthin Dipropionate mp 142o C
    Zeaxanthin Dipalmitate mp 97o C
    Astaxanthin mp 216o C
    Astaxanthin Diacetate mp 205o C
    Capsanthin mp 182o C
    Capsanthin Diacetate mp 150o C
    Capsanthin Dipalmitate mp 95o C
    Crptoxanthin mp 159o C
    Cryptoxanthin Monoacetate mp 117o C
  • It can be observed that the melting points of the pure carotenoids are higher in regard to the melting points of their corresponding derivatives. Therefore in the process to obtain carotenoids derivatives from pure carotenoids, the melting point of oxycarotenoids is reduced from 50 to 116° C with respect to the melting point of the pure carotenoid, when the diacetate derivatives are incorporated in the process; and the melting point of oxycarotenoids is reduced from 30 to 50° C with respect to the melting point of the pure carotenoid, when propionate derivatives are incorporated in the process. As the molecular weight of the carotenoid derivative is larger, then the melting point of such derivative is further reduced, as compared to the melting point of the pure carotenoid. Substances as Tween 80 and/or lecithin or its different compounds, that can be considered as "impurities" (not contaminants) may provoke a sensible reduction of the pure carotenoids melting points. It is important to notice that when the carotenoids derivatives are melt down at such low temperatures, no degradation compounds are obtained in the process.
  • The obtained micelles can be easily dispersed in water, forming stable microemulsions or nanoemulsions, composed of an internal homogeneous lipophilic phase of carotenoids derivatives that do not contain any crystals, and an external hydrophylic phase formed by lipids and emulsifiers. It is a true oxycarotenoid derivatives solute contained in the micelles. Due to its soft nature such lipid carotenoid derivatives can be easily micronized by means of a homogenizing machine into a microemulsion or a nanoemulsion. Crystalline structures per se are hard to break by mechanical means and therefore are very difficult to be worked into microemulsions and almost impossible to produce nanoemulsions in a non polar media.
  • Surprisingly when the lipid oxycarotenoid derivatives microemulsions are incorporated in the feed of laying hens or broilers, the pigmentation efficiency is noticeably improved as compared to the pigmentation obtained by premixes or water dispersions that contain the oxycarotenoids in crystalline form.
  • It is a novelty also to obtain an improved absorption by humans of the oxycarotenoids derivatives as micromicelles in a lipid matrix of free fatty acids, phospholipids, sterols, waxes and different kinds of vegetable or fish oils and emulsifiers; as compared to the absorption of free carotenoids crystals dispersed in oil, regardless of the size of the crystals.
  • EXAMPLES
  • The following examples illustrate the improved absorption and bioavailability of the microemulsions and nanoemulsions obtained from the lipid carotenoid derivatives dispersion. These examples are presented for illustrative purposes only and for a better understanding of the invention. However, they are not intended to limit the scope of the present invention.
  • Example 1.
  • The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • To five (5) kgs of aqueous saponified marigold oleoresin with a pH of 13, a 30 % diluted acetic acid is added with stirring until a pH of 7.0 is obtained. A separation of phases is observed and the aqueous phase is discarded. The organic phase is rinsed several times with 10 kg of lukewarm water to remove acid traces and polar compounds. The water is discarded and the temperature is raised to 90°C and a vacuum of 3mm Hg is applied under agitation. Once all the moisture has been removed from the mass, an amount of acetic anhydride is added slowly according to the process described in US Patent No. 5,959,138 .
  • After the oxycarotenoids diacetate has been formed, the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 1 kg of a vegetable oil or fish oil, fatty acid and an emulsifier mixture is added. The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C
  • An amount of 500 gr of Tween 80 is added and agitated for a period of 120 minutes.
  • Afterwards an amount of 500 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
  • The temperature of the reactor is increased to 100° C until all of the lutein diacetate crystals disappear, as can be observed under a 100X microscope objective.
  • The mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension. The above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature. The colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
  • Example 2.
  • The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • To one kg of aqueous saponified red pepper oleoresin with a pH of 13, a 20 % aqueous phosphoric acid solution is added until a pH of 7.0 is reached upon stirring. A two phase separation is obtained, and the water phase is discarded. The organic phase is rinsed twice with two portions of 10 kgs of lukewarm water to remove acid traces and salts. The organic phase in the closed vessel is subject to a vacuum of 3 mm Hg until all the moisture has been removed. The capsanthin and capsorubin are then converted into diacetates according to the process described in US Patent No.5, 959,138 .
  • After the oxycarotenoids diacetate has been formed, the lipid matrix is incorporated in a suitable reactor under agitation, an amount of 500 gr of oleic acid.
  • The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
  • An amount of 100 gr of polysorbate 60 is added and agitated for a period of 120 minutes.
  • Afterwards an amount of 200 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
  • The temperature of the reactor is increased to 95° C until all of the carotenoids diacetate crystals disappear, as can be observed under a 100X microscope objective.
  • The mass is immediately cooled down to room temperature and 2 kgs of water are added under agitation to obtain a colloidal suspension. The above procedure is carried in a closed vessel in the absence of light and under an atmosphere of nitrogen. This procedure helps the dissolution of crystals and avoids the oxycarotenoids derivatives contained in the original matrix to recrystallize at room temperature. The colloid solution is ready to be dispersed in solid carriers or emulsified in water to the desired concentration.
  • Example 3.
  • The oxycarotenoids derivatives described in the process of the present invention may be obtained by the following process:
  • 100 grams of purified free lutein concentrate (85% by weight, AOAC) are blended with 150 grams of food grade oleic acid and 5 grams of α-tocopherol, and the mass is agitated under vacuum for a time of 120 minutes at 90° C to remove any traces of moisture. Then an amount of acetic anhydride is added according to the process described in US Patent No. 5,959,138 until all of the lutein has been converted into the diacetate.
  • The mass is rinsed several times with lukewarm water several times to remove any acid traces and salts.
  • The vessel is kept under a nitrogen atmosphere and the temperature is risen to 60-70°C .
  • An amount of 20 gr of Tween 80 is added and agitated for a period of 120 minutes.
  • Afterwards an amount of 40 gr of lecithin is added and the mix is stirred for a period of 60 minutes.
  • The temperature is raised to 100°C under an atmosphere of nitrogen for a period of 180 minutes until no carotenoids crystals are observed under a 100X microscope objective.
  • Once the lutein diacetate crystals have melt down, the mass is cooled below 40 °C, 50 grams of water are added and a colloid suspension is obtained in a high speed agitator. The colloidal suspension can be dispersed in solid carriers, vegetable oils or diluted in water.
  • Example 4.
  • Two identical groups (Group A and Group B) of three weeks old broilers were placed in suitable pens, containing 50 chicken each. They were fed identical feeds (ad-libitum) containing different pigmenting concentrates. Group A broilers feed contained 80 ppm of a blend of micellar lutein diacetate and micellar zeaxanthin diacetate prepared according to example 1. Group B broilers feed contained 90 ppm of a standard lutein pigment (saponified and dispersed in water) plus 3 grams of cantaxanthin.
  • After four weeks the broilers were slaugthered, processed and refrigerated. The average deposition of pigment in the broilers shank (palmar tissue) was almost identical: 14.9 ppm of total xanthophylls for Group A; and 15.0 ppm of total xanthophylls for Group B.
  • A Minolta Chromameter was used to determine the pigment reading in the breast skin of each refrigerated broiler. The average readings obtained for each group are as follows:
    Group Yellowness (b*) Redness (a*) Luminosity
    A 27.12 -1.19 76.12
    B 26.21 0.90 74.09
  • The above data show that for a common person no difference can be appreciated by the naked eye among the pigmentation of the two groups.
    However, such information reveals that broilers from Group A, whose feed contained only 80 ppm of micellar lutein diacetate and micellar zeaxanthin diacetate, absorbed much more efficiently the pigment than those from Group B whose feed contained 90 ppm of standard lutein pigment water dispersion plus 3 ppm of red cantaxanthin.
  • Example 5.
  • 10 healthy non smoking students (range 22-27 years), were subject to the following two treatments:
    1. (A) 4 weeks of ingesting one gelatin capsule at noon meal, containing 20 mg of crystalline lutein dispersed in soybean oil and after a 12 hours fast (overnight) blood samples were taken early morning next day for plasma analysis.
    2. (B) After a 2 weeks washout period interval, the same group of subjects were given during a period of 4 weeks a gelatin capsule containing a micellar dispersion of lutein diacetate (prepared as described in example 3) in soybean oil. Each capsule contained 24.2 mg of lutein diacetate and was ingested at lunch time. After 12 hours fast, blood samples were collected early morning next day for plasma analysis.
  • The results obtained were as follow: Table 1 One gel capsule per day containing 20 mg lutein in soybean oil
    Analysis of blood serum in nmol/dL
    Subject 7 days 14 days 21 days 28 days
    A 38.1 38.7 39.2 39.8
    B 23.4 24.8 26.4 27.3
    C 17.5 20.5 23.8 25.1
    D 21.2 23.5 25.2 29.1
    E 20.6 21.5 22.1 22.4
    F 35.7 41.0 46.0 49.7
    G 42.2 44.7 46.6 47.0
    H 15.8 16.4 17.3 19.3
    I 38.1 38.9 40.1 39.2
    J 24.7 25.6 26.6 27.7
    Average 27.7 29.6 31.3 32.6
    Std. Dev. 9.8 10.1 10.6 10.6
    Var. Coef. 0.4 0.3 0.3 0.3
    Max 42.2 44.7 46.6 49.7
    Min 15.8 16.4 17.3 19.3
    Table 2: one gel capsule per day containing 24.2 mg of lutein diacetate in soybean oil
    Analysis of blood serum in nmols/dL
    Subject 7 days 14 days 21 day 28 days
    A 76.3 88.3 99.3 118.7
    B 46.3 51.6 57.1 68.1
    C 31.5 39.3 49.3 65.2
    D 39.4 51.2 63.0 84.1
    E 40.2 46.2 52.5 62.6
    F 66.7 87.1 106.8 146.8
    G 82.3 98.9 113.0 134.0
    H 23.6 29.4 35.6 48.2
    I 71.3 81.8 94.6 115.8
    J 46.6 51.9 60.3 74.1
    Average 52.4 62.6 73.1 91.8
    Std. Dev. 20.2 24.1 27.5 34.2
    Var. Coef. 0.4 0.4 0.4 0.4
    Max 82.3 98.9 113.0 146.8
    Min 23.6 29.4 35.6 48.2
  • The improvement in the absorption and bioavailability can be determined by the ratio of the average absorption of the lutein diacetate (Table 2), divided by the average absorption of the free lutein (Table 1): 91.8/ 32.6 = 2.81 times

Claims (15)

  1. A process for obtaining stable microemulsions that are composed of a solubilizate of derivatives of oxycarotenoids of short chain organic acids, selected from the group consisting of diacetates and dipropionates of lutein, 3'epilutein, zeaxanthin, iso zeaxanthin, meso zeaxanthin, capsanthin, capsorubin, astaxanthin, and cryptoxanthin monoacetate and monopropionate, which are melted down from the naturally occurring original lipid vegetable matrix in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture which are better absorbed and more bioavailable, as compared with oxycarotenoids in crystalline form, which process comprises the steps of:
    a) adding diacetate and dipropionate derivatives of oxycarotenoids with sterols, fatty acids, lipids, phospholipids, emulsifiers, or mixtures thereof, derived from a vegetable matrix in a reactor;
    b) raising the temperature of the reactor to about 60 to about 70.degree. C.;
    c) adding a surfactant to obtain a mixture of derivatives of oxycarotenoids and a surfactant;
    d) stirring the mixture obtained in step c) for a period of time sufficient to homogenize the mixture;
    e) adding to the mixture obtained in step d) from about 5% to about 50%, by weight, of a phospholipid;
    f) stirring the mixture obtained in step e) for a period of time sufficient to homogenize the mix;
    and either
    g) adding to the mixture obtained in step f) about 1% to about 40%, by weight, of water; and
    h) raising the temperature of the mixture obtained in step
    g) to about 90 to about 110⌀ C. while maintaining the pH at from about 5.5 to about 8.5 and refluxing the mixture for a period of time sufficient to melt the crystals of the oxycarotenoids derivatives in the non polar lipid matrix
    or
    g') raising the temperature of the mixture obtained in step f) to about 90 to about 110.degree. C. while maintaining the pH at from about 5.5 to about 8.5 and refluxing the mixture for a period of time sufficient to melt the crystals of the oxycarotenoids derivatives in the non polar lipid matrix whereby microemulsions of the oxycarotenoids derivatives are formed; and
    h') adding to the mixture obtained in step g') about 1% to about 40%, by weight, of water.
    whereby microemulsions of the oxycarotenoids derivatives are formed.
  2. The process as claimed in claim 1, wherein the surfactant comprises from about 5 to 50%, by weight, of a surfactant selected from the group consisting of polyoxyethylene sorbitan, polyoxyethylene stearate, polyoxyethylene oleate polyoxyethylene laureates, sorbitan esters, poloxamers and tyloxapol, and polyoxyethylene fatty acid esters.
  3. The process as claimed in claim 1, wherein the phospholipid is selected from the group consisting of a zwitterionic surfactant; a surfactant consisting of about 70% phosphatidylcholine and 12% phosphatidylethanolamine and about 15% other phospholipids; of a surfactant consisting of phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; or a purified phospholipid mixture, such as that obtained from egg yolk, or a surfactant consisting of about 50% phosphatidylcholine, 5% phosphatidylethanolamine, 3.6% non-polar lipids and about 2% sphingomyeline.
  4. The process as claimed in claim 1, wherein in step g) the mixture comprises fatty acids selected from the group consisting of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, sterols, methyl sterols, vegetable C.sub.40, C.sub.42, and C.sub.46 waxes, tocopherols, tocotrienols, phospholipids, and mixtures thereof.
  5. The process as claimed in claim 1, wherein in step h) the pH is maintained at about 6.5 to about 7.0.
  6. The process as claimed in claim 1, wherein step h) is carried out in a vacuum.
  7. The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media suitable for incorporation in human supplements or foods, or feeds for pets, poultry or aquatic animals.
  8. The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media at a temperature of between about 40 to about 70.degree. C.
  9. The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media to improve the absorption and bioavailability of xanthophylls diacetates and dipropionates obtained from lutein, zeaxanthin, capsanthin and capsorubin for use in the pigmentation of the skin of broilers and egg yolks.
  10. The process as claimed in claim 1, wherein the microemulsions of derivatives of oxycarotenoids are further dispersed in an aqueous or lipid media to improve the absorption and bioavailability of the carotenoids derivatives obtained from lutein, zeaxanthin, capsanthin, capsorubin, and astaxanthin when incorporated in the feed of marine organisms.
  11. The process as claimed in claim 1, wherein the microemulsions of oxycarotenoids derivatives are further dispersed in lipids or water containing carotenoids derivatives obtained from lutein, 3'epilutein, zeaxanthin, isozeaxanthin, mesozeaxanthin, capsanthin, capsorubin, astaxanthin and cryptoxanthin, which can be administered to humans as a supplement to prevent and protect cells and tissues from the damaging effect of free radicals and singlet oxygen, as well as to prevent the risk of cancers and stroke.
  12. The process as claimed in claim 1, wherein the microemulsions of diacetates and dipropionates of oxycarotenoids of lutein, 3'epilutein, zeaxanthin, isozeaxanthin are further dispersed in fish oil with a high content of omega 3 fatty acids which aids in reducing the risk of macular degeneration and the formation of cataracts in humans when ingested.
  13. The process as claimed in claim 1, wherein the microemulsions contains oxycarotenoids derivatives of diacetates or dipropionates of lutein, 3'epilutein, zeaxanthin, Isozeaxanthin, and are further dispersed in fish oil with a high content of omega 3 fatty acids, whereby the cardiovascular health of humans is improved when ingested.
  14. The process as claimed in claim 1, wherein the melting point of the oxycarotenoids are reduced by about 50 to about 116.degree. C. with respect to the melting point of the pure carotenoid when the diacetate derivatives are incorporated in the process and the melting point of the oxycarotenoids is reduced by 30 to 50.degree. C. with respect to the melting point of the pure carotenoid when propionate derivatives are incorporated in the process.
  15. The process as claimed in claim 1, wherein the microemulsions obtained are further reduced in size to obtain nanoemulsions by the use of intense high speed and high shear mechanical agitators, or by emulsifying machines operating at pressures of the order of about 3,000 to about 4,000 psi.
EP07747170.4A 2006-08-18 2007-03-08 A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these Not-in-force EP2062570B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/506,974 US7435846B2 (en) 2006-08-18 2006-08-18 Absorption and bioavailability of carotenoids, formulations and applications
PCT/MX2007/000024 WO2008020747A1 (en) 2006-08-18 2007-03-08 A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these

Publications (3)

Publication Number Publication Date
EP2062570A1 EP2062570A1 (en) 2009-05-27
EP2062570A4 EP2062570A4 (en) 2012-07-25
EP2062570B1 true EP2062570B1 (en) 2014-01-15

Family

ID=39082241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07747170.4A Not-in-force EP2062570B1 (en) 2006-08-18 2007-03-08 A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these

Country Status (4)

Country Link
US (1) US7435846B2 (en)
EP (1) EP2062570B1 (en)
JP (1) JP2010502575A (en)
WO (1) WO2008020747A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4868587B2 (en) * 2006-09-26 2012-02-01 ユニチカ株式会社 Cryptoxanthin-containing composition
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
WO2009112506A1 (en) * 2008-03-11 2009-09-17 Dsm Ip Assets B.V. Novel use of carotenoid (ester)s
US20120157547A1 (en) * 2010-12-21 2012-06-21 Ricardo Montoya-Olvera Compositions and applications of carotenoids of improved absorption and bioavailability
US8754126B2 (en) 2010-12-29 2014-06-17 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
AU2013363208B2 (en) * 2012-12-19 2016-04-14 ew nutrition Carotenoid Technologies S.A.U. Xanthophyll compositions and methods of use
SG11201507212TA (en) 2013-03-13 2015-10-29 Abbott Lab A composition for enhancing newborn infant cognitive, brain and/or cns development and method of using same
CN105188411A (en) * 2013-03-13 2015-12-23 雅培制药有限公司 Method of enhancing bioavailability of DHA and other lipid-soluble nutrients
MY169122A (en) 2013-03-13 2019-02-18 Abbott Lab Infant nutritional product with rrr alpha-tocopherol
WO2015069974A1 (en) * 2013-11-07 2015-05-14 Abbott Laboratories Capsules containing nutritional supplement formulations with enhanced absorption of lipophilic nutrients
KR101699426B1 (en) * 2013-12-11 2017-01-24 헬스-에버 바이오테크 컴퍼니 리미티드 Pharmaceutical compositions of carotenoid
US9622970B2 (en) * 2014-05-08 2017-04-18 Yaguang Liu Pharmaceutical composition containing lutein and antioxidant for treating and preventing human disease
US9968565B2 (en) 2015-03-02 2018-05-15 Omniactive Health Technologies Limited Method for protection and improvement of liver health with meso-zeaxanthin compositions
CN104664168B (en) * 2015-03-16 2018-02-16 广州益牲宝动物药业有限公司 A kind of piglet specific complex vitamin microemulsion preparation and its preparation method and application
IT201700045343A1 (en) * 2017-04-26 2018-10-26 Micro Sphere Sa PROCESS FOR THE PREPARATION OF A FOOD AND SUPPLEMENTARY SUPPLEMENTER SO OBTAINED
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
GB201801986D0 (en) * 2018-02-07 2018-03-28 Ip Science Ltd Anthocyanins and used thereof
JP2024530364A (en) * 2021-07-01 2024-08-19 ケミン、インダストリーズ、インコーポレーテッド Microemulsion bases for improved dye absorption and related methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861891A (en) * 1956-12-13 1958-11-25 Hoffmann La Roche Water dispersible carotenoid compositions and process of making the same
US3523138A (en) * 1965-03-01 1970-08-04 Eastman Kodak Co Treatment of marigold petal meal to obtain a xanthophyll product
US3535426A (en) * 1966-07-08 1970-10-20 Eastman Kodak Co Stabilization of xanthophylls
ATE96312T1 (en) * 1989-07-25 1993-11-15 Hoffmann La Roche PROCESS FOR THE MANUFACTURE OF CAROTINOID PREPARATIONS.
CH681153A5 (en) * 1991-01-28 1993-01-29 Marigen S.A. New and sterolester- sterolphosphorverbindungen.
JPH0538273A (en) * 1991-08-06 1993-02-19 Saneigen F F I Kk Extracted carotene preparation
US6132790A (en) * 1991-09-06 2000-10-17 Betatene Limited Carotenoid composition
DE19609538A1 (en) * 1996-03-11 1997-09-18 Basf Ag Finely divided carotenoid and retinoid suspensions and process for their preparation
CH685189A5 (en) * 1993-11-19 1995-04-28 Marigen Sa Ultramicroemulsions spontaneously dispersible concentrates with antitumoral effective xanthophyll esters.
JPH09157159A (en) * 1995-12-11 1997-06-17 Lion Corp Composition containing carotinoid
US5827539A (en) * 1995-12-28 1998-10-27 Amway Corporation Dry carotenoid-oil powder and process for making same
DE19609476A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable parenteral administration suitable carotenoid emulsions
DE19609477A1 (en) * 1996-03-11 1997-09-18 Basf Ag Stable aqueous solubilisates of carotenoids and vitamins
DE69728206T2 (en) * 1996-05-14 2005-03-10 Dsm Ip Assets B.V. Production process for carotenoid compositions
DE19637517A1 (en) * 1996-09-13 1998-03-19 Basf Ag Production of powdered, cold water dispersible carotenoid preparations and the use of the new carotenoid preparations
TW371619B (en) * 1996-10-07 1999-10-11 Dsm Ip Assets Bv Vitamin preparations for beverage applications
DE19649062A1 (en) * 1996-11-27 1998-05-28 Basf Ag Liquid, oil-miscible carotenoid preparations
JPH1160980A (en) * 1997-08-13 1999-03-05 Kagome Co Ltd Water-dispersible carotenoid pigment preparation
GB9718636D0 (en) * 1997-09-04 1997-11-05 Smithkline Beecham Plc Novel composition and use
US5959138A (en) * 1997-11-25 1999-09-28 Industrial Organica S.A. De C.V. Short chain diesters and process for making the same
CA2261456A1 (en) * 1998-02-23 1999-08-23 F. Hoffmann-La Roche Ag Preparation of a finely divided pulverous carotenoid preparation
WO1999047001A1 (en) 1998-03-18 1999-09-23 Kemin Industries, Inc. Increased bioavailability of lutein and zeaxanthin in humans and poultry using lysolecithin and lecithin
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
JP3803260B2 (en) * 2001-03-23 2006-08-02 伯東株式会社 Skin external preparation for whitening
JP4859006B2 (en) * 2001-05-25 2012-01-18 富士化学工業株式会社 Stable astaxanthin-cyclodextrin inclusion compound and method for producing the same, and liquid, food and drink, feed, pharmaceuticals and cosmetics containing the inclusion compound
ES2607487T3 (en) * 2001-06-14 2017-03-31 San-Ei Gen F.F.I., Inc. Carotenoid color emulsion preparation
US6635293B2 (en) * 2001-10-23 2003-10-21 Kemin Foods, L.C. Finely dispersed carotenoid suspensions for use in foods and a process for their preparation
US6936279B2 (en) * 2002-06-18 2005-08-30 Zeavision Llc Microcrystalline zeaxanthin with high bioavailability in oily carrier formulations

Also Published As

Publication number Publication date
EP2062570A1 (en) 2009-05-27
EP2062570A4 (en) 2012-07-25
WO2008020747A1 (en) 2008-02-21
US7435846B2 (en) 2008-10-14
US20080044475A1 (en) 2008-02-21
JP2010502575A (en) 2010-01-28

Similar Documents

Publication Publication Date Title
EP2062570B1 (en) A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these
CN1094326C (en) Carotenoid preparation having mixture of beta-carotene, lycopene and xanthophyll
JP4988081B2 (en) Stable lycopene powder formulations, stable lycopene aqueous dispersions, their preparation, their use and nutritional supplements containing them, animal feed, food, and pharmaceuticals and cosmetics
US10004670B2 (en) Ready-to-use, stable emulsion
US20230063291A1 (en) Stable carotenoid microcapsule having high bioavailability and preparation method therefor
US20150265638A1 (en) Absorption of fat-soluble nutrients
JP5936796B1 (en) Emulsified composition
CN109157510A (en) A kind of water-soluble carotenoid preparation and the preparation method and application thereof
JP2009142180A (en) Packaged beverage
JP2010515446A (en) Oily composition
JP2009062330A (en) Powder composition
US20140099386A1 (en) Compositions and applications of carotenoids of improved absorption and bioavailability
JP2000106844A (en) Water-dispersible carotenoid composition
US20120157547A1 (en) Compositions and applications of carotenoids of improved absorption and bioavailability
JP5631941B2 (en) Container drink
CA2331661A1 (en) Use of 'nanofood' in foodstuff final products for humans and animals
JP5878590B2 (en) Container drink
Chow et al. The effect of dietary carotenoids of different forms: microemulsified and non-microemulsified on the growth performance, pigmentation and hematological parameters in hybrid catfish (Clarias macrocephalus× Clarias gariepinus)
ES2740627T3 (en) Astaxanthin (IV) compositions
EP3270904B1 (en) Astaxanthin compositions (i)
WO2016146803A1 (en) Astaxanthin compositions (iii)
JP2009060825A (en) Powder composition comprising oil-soluble component, and functional food product employing the same
EP4418865A1 (en) Liquid composition containing a combination of vitamins a, d, e and k in a liquid matrix
JP2012040018A (en) Packaged beverage
CN111358000A (en) Oily composition containing carotene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090312

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120622

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 1/303 20060101ALI20120618BHEP

Ipc: A61K 9/48 20060101ALI20120618BHEP

Ipc: A61K 31/22 20060101ALI20120618BHEP

Ipc: A23L 1/275 20060101ALI20120618BHEP

Ipc: A61K 9/107 20060101AFI20120618BHEP

Ipc: A23L 2/58 20060101ALI20120618BHEP

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 1/035 20060101ALI20130524BHEP

Ipc: A61K 9/48 20060101ALI20130524BHEP

Ipc: A23K 1/16 20060101ALI20130524BHEP

Ipc: A23L 1/30 20060101ALI20130524BHEP

Ipc: A23K 1/18 20060101ALI20130524BHEP

Ipc: A61K 9/107 20060101AFI20130524BHEP

Ipc: A61K 31/22 20060101ALI20130524BHEP

INTG Intention to grant announced

Effective date: 20130617

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20131120

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 649453

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007034795

Country of ref document: DE

Effective date: 20140227

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140115

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 649453

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140115

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140515

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007034795

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140308

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

26N No opposition filed

Effective date: 20141016

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140415

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20141128

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007034795

Country of ref document: DE

Effective date: 20141001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140308

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140415

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140416

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070308

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140115